8:00 AM - 5:00 PM
YOU'RE INVITED: Inaugural Optic Disc Drusen Virtual Conference
MONDAY, MAY 11, 2020 (8 AM- 5 PM)
UPDATE AS OF 5/19:
Thank you for your interest on the Stanford Center for Optic Disc Drusen. We had a successful international meeting of about 450 participants from 35 countries on May 11, 2020. We are working hard to make the meeting video available soon.
We will email attendees the announcement for the 2021 meeting unless you tell us not to do so.
The Stanford Center for Optic Disc Drusen at the Byers Eye Institute is hosting an international virtual conference to share laboratory and clinical advances and seed collaborative opportunities, to educate the public about the state of optic disc drusen research, and to strategize about how to rapidly advance the field. Optic disc drusen are calcified deposits found at the anterior optic nerve in about 2% of the general population. It is an important risk factor for optic neuropathy and vision loss.
Because of the COVID-19 pandemic, this meeting will be virtual through Zoom. We are aware that this is an extremely challenging time for many people, and our sincere thoughts go out to the many who are suffering during this unprecedented crisis. Despite this difficult time, we decided against postponing or canceling the meeting, because we want to fulfill our mission to advance research in this important disease.
Registration is free. If you are interested in participating, please register by clicking “register to get zoom link” or scan the QR code. Both will take you to our website. Those who register will receive detailed information about the meeting. While we will not be offering CME credit for this 2020 meeting, we hope to in the future. For those unable to attend, a videotaped version of the meeting will be placed on the website after.
This event features over 20 talented speakers from Stanford and beyond. There will be sessions on optic disc drusen, advance ophthalmic imaging approaches, novel animal models of disease, genetic studies, and design of future clinical trials. The first portion will consist of clinical and scientific talks, and the second portion will feature stories from patients and their families.
Joyce Liao, MD, PhD & Jeffrey Goldberg, MD, PhD